NASDAQ: IMRXImmuneering Corp Stock Ownership - Who owns Immuneering?
Insider buying vs selling
Have Immuneering Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Peter Feinberg | Director | 2025-10-03 | 7,500 | $6.67 | $50.03kBuy |
| Michael Bookman | CHIEF LEGAL OFFICER SECRETARY | 2025-10-01 | 1,020 | $6.83 | $6.97kBuy |
| Leah R. Neufeld | CHIEF PEOPLE OFFICER | 2025-10-01 | 800 | $6.38 | $5.10kBuy |
| Mallory Morales | Chief Accounting Officer | 2025-10-01 | 300 | $6.39 | $1.92kBuy |
| Peter Feinberg | Director | 2025-09-30 | 7,500 | $7.03 | $52.73kBuy |
| Peter Feinberg | Director | 2025-09-29 | 5,000 | $7.18 | $35.90kBuy |
| Leah R. Neufeld | CHIEF PEOPLE OFFICER | 2025-09-15 | 11,815 | $1.43 | $16.87kBuy |
| Mallory Morales | Chief Accounting Officer | 2025-09-15 | 14,497 | $1.43 | $20.70kBuy |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | 2025-09-15 | 14,880 | $1.43 | $21.25kBuy |
| Benjamin J. Zeskind | PRESIDENT AND CEO | 2025-07-02 | 7,015 | $3.53 | $24.79kBuy |
IMRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when IMRX insiders and whales buy or sell their stock.
IMRX Shareholders
What type of owners hold Immuneering Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Fmr LLC | 13.61% | 8,787,052 | $56.24M | Institution |
| Cormorant Asset Management LP | 11.00% | 7,099,637 | $45.44M | Insider |
| Benjamin J. Zeskind | 5.81% | 3,752,706 | $24.02M | Insider |
| Sanofi | 4.19% | 2,708,559 | $17.33M | Institution |
| Vanguard Group Inc | 3.74% | 2,415,244 | $15.46M | Institution |
| Price T Rowe Associates Inc | 2.79% | 1,798,782 | $11.51M | Institution |
| Exoduspoint Capital Management LP | 2.35% | 1,516,833 | $9.71M | Institution |
| Peter Feinberg | 2.29% | 1,480,798 | $9.48M | Insider |
| Robert J. Carpenter | 1.78% | 1,148,839 | $7.35M | Insider |
| Logos Global Management LP | 1.47% | 950,000 | $6.08M | Institution |
IMRX vs Biotech Stocks
Immuneering Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.